Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial.

ABSTRACT:

Background

Agitation is common in the early stages of recovery from traumatic brain injury (TBI), when patients are in post-traumatic amnesia (PTA). Agitation is associated with risk of harm to patients and caregivers. Recent guidelines recommend that agitation during PTA is managed using environmental modifications. Agitation is also frequently treated pharmacologically, with the use of atypical antipsychotics such as olanzapine among the most common. This is despite a lack of well-designed studies to support the use of antipsychotics within this context. This study will be a double-blind, placebo-controlled randomised controlled trial. We will examine the efficacy, safety, cost-effectiveness and outcomes associated with the use of olanzapine for reducing agitation in patients in

SUBMITTER: Phyland RK 

PROVIDER: S-EPMC7370410 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature